Erythropoietin beim multiplen Myelom

Translated title of the contribution: Erythropoietin in multiple myeloma

M Pecherstorfer, F Schmoranzer, M Vesely, A Fortelny, G Baumgartner

Research output: Journal article (peer-reviewed)Journal article

5 Citations (Scopus)


In a 59-year-old man with multiple myeloma (kappa-light chain paraproteinaemia) in stage IIIB, bone marrow infiltration with atypical plasma cells was reduced by five cytostatic treatment courses with vincristine, melphalan, cyclophosphamide and prednisone (VMCP protocol), but anaemia requiring blood transfusion persisted (haemoglobin concentration 5.3 g/dl). Even administration of interferon alpha-2b (5 million units s.c. every other day) failed to alter this. Only a combination of interferon and erythropoietin (150 U/kg i.v. every other day) achieved lasting regression of the anaemia (haemoglobin concentration up to 14 g/dl). In four other anaemic patients with multiple myeloma, stage III, treated according to the VMCP protocol but without additional interferon, erythropoietin did not improve erythropoiesis.

Translated title of the contributionErythropoietin in multiple myeloma
Original languageGerman
Pages (from-to)1096-9
Number of pages4
JournalDeutsche Medizinische Wochenschrift
Issue number28-29
Publication statusPublished - 13 Jul 1990
Externally publishedYes


Dive into the research topics of 'Erythropoietin in multiple myeloma'. Together they form a unique fingerprint.

Cite this